Pharmacokinetic Evaluation of [(11)C]CEP-32496 in Nude Mice Bearing BRAF(V600E) Mutation-Induced Melanomas

CEP-32496, also known as RXDX-105 or Agerafenib, is a new orally active inhibitor for the mutated v-raf murine sarcoma viral oncogene homolog B1 (BRAF(V600E)), which has attracted considerable attention in clinical trials for the treatment of human cancers. Here, we used carbon-11-labeled CEP-32496...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Cuiping, Xie, Lin, Zhang, Yiding, Fujinaga, Masayuki, Mori, Wakana, Kurihara, Yusuke, Yamasaki, Tomoteru, Wang, Feng, Zhang, Ming-Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156206/
https://www.ncbi.nlm.nih.gov/pubmed/30251592
http://dx.doi.org/10.1177/1536012118795952

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156206/
https://www.ncbi.nlm.nih.gov/pubmed/30251592
http://dx.doi.org/10.1177/1536012118795952

Ejemplares similares